Gevokizumab
Product Specifications
UNSPSC Description
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II)[1][2].
Target Antigen
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/gevokizumab.html
Purity
98.12
Solubility
10 mM in DMSO
Smiles
[Gevokizumab]
References & Citations
[1]Issafras H, et al. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties. J Pharmacol Exp Ther. 2014 Jan;348(1):202-15. |[2]Roubille F, et al. The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis. 2014 Oct;236(2):277-85.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99171/Gevokizumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99171/Gevokizumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
1129435-60-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6222316-01 0.1 mL
GATAD2A (Transcriptional Repressor p66-alpha, Hp66alpha, GATA Zinc Finger Domain-containing Protein 2A, FLJ20085, FLJ21017) (MaxLight 650)
Ask
View Details 
MBS6222316-02 5x 0.1 mL
GATAD2A (Transcriptional Repressor p66-alpha, Hp66alpha, GATA Zinc Finger Domain-containing Protein 2A, FLJ20085, FLJ21017) (MaxLight 650)
Ask
View Details 